Medera (www.medera.bio) is a private clinical-stage biopharmaceutical company focused on treatments for severe cardiac diseases through next-generation AAV gene therapy. Founded in 2014 by world-renowned experts in cardiac cell and gene therapy from Johns Hopkins and Mass General Brigham, the Company is focused on developing treatments for both prevalent and orphan cardiac diseases. Medera’s pipeline is comprised of three Phase 1/2 programs: SRD-002 for heart failure with preserved ejection fraction (HFpEF), SRD-001 for heart failure with reduced ejection fraction (HFrEF), and SRD-003 Duchenne muscular dystrophy associated cardiomyopathy (DMD-CM). The Company has generated promising human proof-of-concept data from its HFpEF and HFrEF trials to date, with further data from all three Phase 1/2 programs anticipated in 2026.